Murmurs from the heart (or why the stethoscope is not an economic tool).
作者信息
Aristides M, Gliksman M
出版信息
Heart. 1998 Jan;79(1):10-1. doi: 10.1136/hrt.79.1.10.
Abstract
摘要
相似文献
1
Murmurs from the heart (or why the stethoscope is not an economic tool).心脏杂音（或为何听诊器并非一种经济工具）。
Heart. 1998 Jan;79(1):10-1. doi: 10.1136/hrt.79.1.10.
2
Enthusiasm, reality, and cost-effectiveness analysis.热情、现实与成本效益分析。
Heart. 1998 Jan;79(1):9-10. doi: 10.1136/hrt.79.1.9.
3
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.评估心血管治疗价值中的经济学与成本效益。阿昔单抗的应用：比较经济数据。
Am Heart J. 1999 May;137(5):S123-5. doi: 10.1016/s0002-8703(99)70445-x.
4
Routine use of abciximab in coronary stenting?冠状动脉支架置入术中阿昔单抗的常规应用？
Lancet. 1998 Jul 11;352(9122):81-2. doi: 10.1016/s0140-6736(98)85003-4.
5
The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
S Afr Med J. 1998 Feb;88(2):130-1.
6
Cost and outcomes analysis of abciximab use in a community teaching hospital.
Am J Health Syst Pharm. 1998 Dec 15;55(24 Suppl 4):S35-7. doi: 10.1093/ajhp/55.suppl_4.S35.
7
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
Am Heart J. 1999 May;137(5):S129-32. doi: 10.1016/s0002-8703(99)70447-3.
8
9
Abciximab therapy in percutaneous intervention: economic issues in the United States.
Am Heart J. 1998 Apr;135(4):S90-7. doi: 10.1016/s0002-8703(98)70301-1.
10
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.急性冠状动脉综合征治疗的成本与效果：EPIC研究中高危患者接受经皮腔内冠状动脉成形术时阿昔单抗的情况。评估7E3预防缺血性并发症的效果。
Am Heart J. 1998 Apr;135(4):S98-106. doi: 10.1016/s0002-8703(98)70302-3.
引用本文的文献
1
Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.阿昔单抗。其在经皮冠状动脉血运重建中应用的药物经济学综述。
Pharmacoeconomics. 1999 Dec;16(6):711-41. doi: 10.2165/00019053-199916060-00009.
Zotero 插件